Browsing by Author "Božanović, Tatjana (57200447516)"

Background: Premature ovarian failure (POF) can be found in 1% of women at the age of 35-40, mos‌tly due to un-known causes. PI3K-Akt signaling is associated with both ovarian function and growth of primordial follicles. In this s‌tudy, we examined the effects of autologous in vitro ovarian activation with s‌tem cells and autologous growth factors on reproductive and endocrine function in patients with ovarian impairment. Materials and Methods: The longitudinal prospective observational s‌tudy included 50 patients (between 30 and 50 years) with a diagnosis of POF and infertility. This multicenter s‌tudy was performed at Jevremova Special Hospital in Belgrade, Saint James Hospital (Malta), and Remedica Skoplje Hospital, between 2015 and 2018. All patients went through numerous laboratory tes‌tings, including hormonal s‌tatus. The autologous bone marrow mesenchymal s‌tem cells (BMSCs) and growth factors were used in combination for activation of ovarian tissue before its re-transplanta-tion. The software package SPSS 20.0 was used for s‌tatis‌tical analysis of the results. Results: Differences in follicle s‌timulating hormone (FSH), luteinizing hormone (LH), es‌tradiol (E2), and proges‌ter-one (PG) hormone concentrations before and after 3, 6, and 12 months pos‌t-transplantation were tes‌ted in correlation with the volume of transplanted ovarian tissue. A significant correlation (P=0.029) was found between the change in E2 level after 3 months and the volume of re-transplanted tissues. Also after re-transplantation, 64% of the patients had follicles resulting in aspiration of oocytes in 25% of positive women with follicles. Conclusion: The SEGOVA method could potentially solve many human reproductive problems in the future due to the large number of patients diagnosed with POF, as well as the possibility of delaying menopause, thus improving the quality of life and general health (Regis‌tration number: NCT04009473). © 2021, Royan Institute (ACECR). All rights reserved.

General ethical principles such as respect for autonomy and justice could probably be unique around the world but there is an enormous diversity of medical care possibilities that are provided for patients around the globe, and therefore different approaches should be considered depending on the level of health care provided. © 2018 Walter de Gruyter GmbH, Berlin/Boston.

New biotechnology procedures have been introduced to the field of reproductive and perinatal medicine to find solutions for the successful reproduction, as well as disturbances responsible for maternal and perinatal morbidity. Ultrasound plays a crucial role in the early detection of reproductive disorders and perinatal medicine, where biological therapies can be possibly applied. Besides, these techniques require precise monitoring of the application of the biological agent, for which ultrasound is a sovereign method. The use of autologous sources, such as platelet-rich plasma and bone marrow-derived stem cells, provides a wide range of therapeutic strategies for gonadal failure and endometrium therapy. Stem cells from amniotic fluid could be used as the sources for direct fetal treatment in different fetal disorders (neurological disorders, the intrauterine growth restriction). Maternal complications, such as premature rupture of the amniotic sac and disturbed placental adherence, are being successfully treated with the use of biological autologous fibrin tissue adhesives. Postpartum complications related to the change of the pelvic floor could be prevented by the peripartal local application of growth factors and/or stem cells. Subcellular therapies, as microvesicles/ exosomes are membrane-bound biological nanoparticles secreted from stem cells. These particles are variable source that could act as another source of factors that could affect molecular cascades, emerging as a new diagnostic and therapeutic tool in reproductive and perinatal medicine. © The Author(s). 2020.